Alnylam Pharmace. buy William Blair
Start price
08.04.24
/
50%
€143.80
Target price
08.04.25
-
Performance (%)
42.21%
End price
09.04.25
€204.50
Summary
This prediction ended on 09.04.25 with a price of €204.50. With a performance of 42.21% the BUY prediction by William_Blair was a big success. William_Blair has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Alnylam Pharmace. | -5.610% | -5.610% | -13.379% |
| iShares Core DAX® | -1,02 % | -1,14 % | 1,59 % |
| iShares Nasdaq 100 | -2,52 % | -5,25 % | 26,60 % |
| iShares Nikkei 225® | -4,44 % | -10,16 % | 53,01 % |
| iShares S&P 500 | -1,23 % | -0,04 % | 21,56 % |
Comments by William_Blair for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at William Blair.
Ratings data for ALNY provided by MarketBeat
In the thread Trading Alnylam Pharmace.
Die von William_Blair gewählte maximale Laufzeit wurde überschritten